Dengue virus type 2 membrane protein (DENV2 M protein)

The Dengue virus type 2 membrane protein (M protein) is a small structural component of the viral envelope derived from the cleavage of its precursor, prM. During the viral life cycle, the prM protein acts as a molecular chaperone for the envelope (E) protein, shielding its fusion loop to prevent premature membrane fusion within the acidic environment of the host's secretory pathway (UniProt: P07564). As the virus particles transit through the Trans-Golgi Network, the host protease furin cleaves prM into the mature M protein and a 'pr' peptide, which is released upon viral exit, rendering the virion fully infectious (PubMed: 18451167). This protein is a central target for vaccine development, as seen in the recombinant tetravalent vaccines like Qdenga and Dengvaxia, which utilize the prM and E sequences to elicit immune responses (PubMed: 31697510). Furthermore, researchers investigate small molecules that can inhibit the prM-to-M maturation process, thereby neutralizing the virus by trapping it in an immature, non-infectious state. A primary therapeutic challenge remains the risk of antibody-dependent enhancement (ADE), where antibodies targeting the M protein may inadvertently facilitate viral entry into Fc-receptor-bearing cells, potentially worsening the clinical severity of the infection.

Other names

M proteinPre-membrane proteinprM proteinSmall envelope proteinDENV2 prM

Induction of neutralizing antibodies against the prM/M complex to prevent viral maturation; inhibition of furin-mediated cleavage of prM to M to produce non-infectious virions; stabilization of the envelope protein complex.